MicroRNAs each regulate multiple messenger RNAs in the body. InteRNA Technologies aims to develop improved treatments for cancer by harnessing microRNAs, or miRNAs, as therapeutics with more than one mode of action. CEO Roel Schaapveld discussed the company’s work, the challenges it still faces, and its preparations to enter clinical development.
BIO-Europe Spring 2019: InteRNA Sees MicroRNA Potential In Cancer Therapy
Roel Schaapveld is CEO of Dutch microRNA specialist InteRNA Technologies. He spoke to Mike Ward about the company’s therapeutic approach.
More from R&D
More from Scrip
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.